CD38 and neoplasm: As an alternative immune checkpoint molecule that is involved in tumor immune-evasive responses, CD38 is associated with resistance to immune checkpoint inhibitor therapy and likely participates in hyper-progressive tumor growth via the activation of hypoxic pathways, adenosine receptors, and activation-induced cell death (AICD)-dependent T-cell depletion [178].